AbbVie's etentamig achieves 60% progression risk reduction in Phase III CERVINO trial for relapsed-refractory multiple ...

Hengrui's oral GLP-1 agonist HRS-7535 gains China regulatory acceptance for obesity and type 2 diabetes treatment. Latest ...

ARPA-H selects five teams for $125M in genetic medicine manufacturing. Discover how distributed production could revolutionize RNA-based treatments ...

Servier secures exclusive option to Luxna's XNA chemistry platform for antisense oligonucleotide neurological programs. Discover the collaboration details.

Kali Therapeutics receives FDA clearance for KT501 tri-specific T-cell engager in rheumatoid arthritis. Clinical trials ahead ...

France's drug regulator clears SENS-601, an AAV gene therapy for GJB2-related hearing loss. Learn about this breakthrough in ...

Gan & Lee Pharmaceuticals licenses bofanglutide European rights to Menarini Group for EUR 726 million. GLP-1 RA obesity ...

Revolution Medicines' Rasonque demonstrates 42% response rate in previously treated RAS-mutant NSCLC. Phase I/II data ...

NMPA accepts Hansoh's HS-20093, a B7-H3 ADC for post-platinum small cell lung cancer. First ADC filing in indication. Learn ...

Vincere Biosciences receives $1.3M NIDDK SBIR Phase II grant for USP30 inhibitor IND-enabling studies in acute kidney injury treatment. Learn more.

Boston Children's Hospital secures $3.9M NIH grant to develop new treatments for endometriosis pain using lipid receptors. Discover breakthrough research.

GentiBio receives $1.07M NIH grant for engineered Treg therapy in type 1 diabetes. Discover breakthrough in allogeneic cell therapy treatment.